Relationship between C peptide and chronic complications in type-2 diabetes mellitus

Journal of the National Medical Association

Volumn 97, Issue 8, 2005, Pages 1113-1118

  Sari, Ramazan ^a,b   Balci, Mustafa Kemal ^a,b  

^a Department of Internal Medicine ^*

^b AKDENIZ UNIVERSITY   (Turkey)

Author keywords

C peptide; Chronic complications; Type 2 diabetes mellitus

Indexed keywords

C PEPTIDE; GLUCOSE; HEMOGLOBIN A1C; LIPID;

ADULT; AGED; ARTICLE; AUTONOMIC NEUROPATHY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSORY NEUROPATHY; SMOKING;

ADULT; AGED; C-PEPTIDE; CHRONIC DISEASE; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; RISK FACTORS; STATISTICS, NONPARAMETRIC;

EID: 23244458142     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Lee TS, Saltsman KA, Ohashi H, King GL. Activation of protein kinase C by elevation of glucose concentration: proposal for a mechanism in the development of diabetic vascular complications. Proc Natl Acad Sci U S A. 1989;86:5141-5145.
2. The Diabetes and Complication Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl Med. 1993;329:977-986.
3. U.K. Prospective Study (UKPDS). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type-2 diabetes. Lancet. 1998;352:837-853.
4. Bain SC, Chowdhury TA. Genetics of diabetic nephropathy and microalbuminuria. J R Soc Med. 2000;93:62-66.
5. Knowler WC, Bennett PH, Ballintine EJ. Increased incidence of diabetic retinopathy with elevated blood pressure. N Engl J Med. 1980;302:645-650.
6. Polonsky KS. The B-cell in diabetes: from molecular genetics to clinical research. Diabetes. 1995;44:705-717.
7. Barakat HA, Carpenter JW, McLendon VD, et al. Influence of obesity, impaired glucose tolerance and NIDDM on LDL structure and composition. Possible link between hyperinsulinemia and atherosclerosis. Diabetes. 1990;39:1527-1533.
8. Standl E, Janka HU. High serum insulin concentrations in relation to other cardiovascular risk factors in macrovascular disease of type-2 diabetes. Horm Metab Res. 1985;15(suppl):46-51.
9. Mosier MA. Circulating C peptide and diabetic retinopathy. Diabetes Res. 1984;1:151-154.
10. Suzuki K, Watanabe K, Motegi T, et al. High prevalence of proliferative retinopathy in diabetic patients with low pancreatic B-cell capacity. Diabetes Res Clin Practice. 1989;6:45-52.
11. Inukai T, Matsutoma R, Tayama K, et al. Relation between the serum level of C peptide and risk factors for coronary heart disease and diabetic microangiopathy in patients with type-2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 1999;107:40-45.
12. Madsbad S, Lauritzen E, Faber OK, et al. The effect of residual beta-cell function on the development of diabetic retinopathy. Diab Med. 1986;3:42-45.
13. Boz M, Scheen AJ, Gerard PL, et al. Retinopathy, but not neuropathy, is influenced by the level of residual endogenous insulin secretion in type-2 diabetes. Diabetes Metab. 1995;21:353-359.
14. Klein R, Klein BE, Moss SE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XVI. The relationship of C peptide to the incidence and progression of diabetic retinopathy. Diabetes. 1995;44:796-801.
15. Retinopathy Working Party. A protocol for screening for diabetic retinopathy in Europe. Diabet Med. 1991;8:263-267.
16. Feldt-Rasmussen B, Mathiesen ER, Hegedus L, Deckert T, Kidney function during 12 months of strict metabolic control in insulin-dependent diabetic patients with incipient nephropathy. N Engl J Med. 1986;314:665-670.
17. Ewing JE, Martyn CN, Young RJ, et al. The value of cardiovascular autonomic function tests: 10 years experience in diabetes. Diabetes Care. 1985;5:491-498.
18. Niskanen LK, Uusitupa MI, Sarlund H, et al. Five-year follow-up study on plasma insulin levels in newly diagnosed NIDDM patients and nondiabetic subjects. Diabetes Care. 1990;13:41-48.
19. Lev-Ran A, Hwang DL. C peptide in NIDDM: follow-up for 4-6 years. Diabetes Care. 1993;16:76-81.
20. Clauson P, Lmnarsson R, Gottsaler A, et al. Relationship between diabetes duration, metabolic control and beta-cell function in a representative population of type-2 diabetic patients in Sweden. Diabet Med. 1994; 11:794-801.
21. Niskanen L, Karjalainen J, Siitonen O, et al. Metabolic evolution of type-2 diabetes a 10-year follow-up from the diagnosis, J Intern Med. 1994;236:263-270.
22. Haupt E, Haupt A, Herrmann R, et al. The KID study V. The natural history of type 2 diabetes in younger patients still practicing a profession. Heterogenity of basal and reactive C peptide in relation to BMI, duration of disease, age and HbA1c. Exp Clin Endoc Diab. 1999;107:236-243.
23. Lev-Ran A, Hwang D, Barseghian G, et al. Control of noninsulin-dependent diabetes is not correlated with endogenous insulin secretion. Diabetes Metab. 1986;12:325-328.
24. Brichard SM, Van den Abbeele E, Ketelslegers JM, et al. Home blood glucose monitoring, glycosylated hemoglobin and fructosamine: their relationship in diabetic patients with and without residual C-peptide secretion. Diabetes Metab. 1989;15:388-393.
25. Every NR, Boyko EJ, Keane EM, et al. Blood pressure, insulin and C-peptide levels in San Luis Valley, CO. Diabetes Care. 1993;16:1543-1550.
26. Bo S, Cavallo-Perin P, Gentile L, et al. Relationship of residual beta-cell function, metabolic control and chronic complications in type-2 diabetes mellitus, Acta Diabetol. 2000;37:125-129.
27. Austin MA. Plasma triglyceride and coronary heart disease. Arteriosclerosis. 1991;11:2-14.
28. Winocour PH, Jeacock J, Kalsi P, et al. The relevance of persistent C-peptide secretion in type-1 (insulin-dependent) diabetes mellitus to glyceamic control and diabetic complications. Diabetes Res Ciin Pract. 1990;9:23-35.
29. Shin SJ, Lee YJ, Hsaio PJ, et al. Relationships between B-cell function and diabetic duration and albuminuria in type-2 diabetes mellitus. Pancreas. 1997;14:192-198.
30. Smith RB, Pyke DA, Watkins PJ, et al. C-peptide response to glucagon in diabetics with and without complications. N Z Med J. 1979;89:304-306.
31. Snehalatha C, Mohan R, Mohan V, et al. Pancreatic B-cell function in relation to diabetic retinopathy in Asian Indian NIDDM patients. Acta Diabetol Lat. 1988;25:95-100.
32. Klein R, Moss SE, Klein BAK, et al. Wisconsin Epidemiologic Study of Diabetic Retinopathy. XII. Relationship of C Peptide and Diabetic Retinopathy. Diabetes. 1990;39:1445-1450.
33. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med. 1984;310:356-360.
34. Groop L, Ekstrand A, Forsblom C, et al. Insulin resistance, hypertension and microalbuminuria in patients with type-2 (noninsulin-dependent) diabetes mellitus. Diabetologia. 1993;36:642-647.
35. Samnegard B, Jacobson SH, Jaremko G, et al. C peptide prevents glomerular hypertrophy and mesangial matrix expansion in diabetic rats. Nephrol Dial Transplant. 2005;20:532-538.
36. Sjoberg S, Gunnarsson R, Gjotterberg M, et al. Residual insulin production, glycemic control and prevalence of microvascular lesions and polyneuropathy in long-term type-1 (insulin-dependent) diabetes mellitus. Diabeologia. 1987;30:208-213.
37. Toyry JP, Niskanen LK, Mantysaari MJ, et al. Do high proinsulin and C-peptide levels play a role in autonomic nervous dysfunction?: Power spectral analysis in patients with non-insulin-dependent diabetes and nondiabetic subjects, Circulation. 1997;96:1185-1191.
38. Vanninen E, Uusitupa M, Lansimies E, et al. Effect of metabolic control on autonomic function in obese patients with newly diagnosed type-2 diabetes. Diabet Med. 1993;10:66-73.
39. Gottsater A, Ahmed M, Fernlund P, et al. Autonomic neuropathy in type-2 diabetic patients is associated with hyperinsulinemia and hypertriglyceridemia. Diabet Med 1999;16:49-54.
40. Maser RE, Steenkiste AR, Dorman JS, et al. Epidemiological correlates of diabetic neuropathy. Report from Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes. 1989;38:1456-1461.
41. King GL, Buzney SM, Kahn CR, et al. Differential responsiveness to insulin of endothelial and support cells from micro- and macrovessels. J Clin Invest. 1983;71:974-979.